Vera <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports Q3 net loss of $80.3 million
Vera Therapeutics Inc. reported a net loss of $80.3 million, or $1.26 per diluted share, for the quarter ended September 30, 2025, compared to a net loss of $46.6 million, or $0.85 per diluted share, for the same period in 2024. Net cash used in operating activities during the nine months ended September 30, 2025, was $171.1 million, up from $95.5 million in the previous year. As of September 30, 2025, the company held $497.4 million in cash, cash equivalents, and marketable securities. Vera Therapeutics expects its current funds to be sufficient to support operations through the potential approval and U.S. commercial launch of atacicept and beyond. The company is preparing for a Biologics License Application submission for atacicept for the treatment of IgA nephropathy in adults, expected in the fourth quarter of 2025, with potential FDA approval and U.S. launch in 2026. Vera is also actively enrolling patients in the PIONEER, atacicept monthly dose range finding, and ORIGIN Extend studies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569142-en) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.